Niemann-Pick Disease type C (NP-C, OMIM #257220) is a lysosomal storage disorder caused by abnormal intracellular lipid accumulation which results from a mutation in genes encoding either NP-C1 (95% of patients) or NP-C2 (5%) proteins [3, 4] . Clinical symptoms of NP-C are progressive and are primarily neurological. One of the earliest, and most distinct, neurological symptoms of NP-C is vertical supranuclear gaze palsy (VSGP) [5] [6] [7] . Initially only vertical eye-movements are affected, but later both horizontal and vertical movements become abnormal [8] . This results from cell loss in the rostral interstitial nucleus of the medial longitudinal fasciculus (RIMLF), responsible for vertical saccades, and eventually in the paramedian pontine reticular formation (PPRF), responsible for horizontal saccades. The integrity of excitatory burst neurons in these nuclei is related to peak saccade velocity, which has been shown to be a useful index of dysfunction in the RIMLF and PPRF [9, 10] . In addition, a strictly upward movement requires balanced excitation in two populations of neurons. Neurons in RIMLF that code upward and left torsion must be balanced by neurons that code upward and right torsion so that the two torsional instructions cancel out [10] . Damage that is distributed over RIMLF will often produce asymmetries in the two populations coding for vertical movements. We will show that the details of RIMLF population coding, as described by Crawford and Vilis [11] in their stimulation and activation study, predict both the slowing and curvature that we see in our NP-C results. Our results, as a consequence, add evidence to support the functional description they provide.
Detailed reports of oculomotor dysfunction exist in adult NP-C patients [2, 8] , where vertical saccade degeneration is absolute. Detailed information about the onset and progression of vertical saccade degeneration during early stages of the disease, most often in childhood, is lacking. This is a clinically important gap because the only approved treatment of NP-C (miglustat, or Zavesca, Actelion, a small iminosugar that inhibits glucosylceramide synthesis) slows neurodegeneration [12] [13] [14] [15] but is prescribed only once neurological involvement (e.g. gaze palsy or ataxia) has been detected. Established clinical severity scales aimed at tracking the neurological progression of NP-C exist [16] . However, these are based on a bedside examination of eye movements. Bedside examination will not be able to measure changes with the same sensitivity as modern eye-trackers which sample eye position up to 1000 times a second. These offer the potential to detect the eye movement changes much earlier. We tested techniques designed to identify changes to eye movements, and, therefore, the onset of neurodegeneration earlier. This could allow clinicians to make decisions sooner that are aimed at maintaining patient abilities at the highest possible level.
In this study, we established norms for oculomotor developmental change in a large sample of control children and compared NP-C patients to the control range to see if this allowed neurological impairment to be detected using eye-tracking before it is evident with standard clinical methods.
Methods
Patient Information. Five paediatric NP-C patients were recruited from NP-C clinics at Birmingham Children's Hospital and Great Ormond Street Hospital (mean age= 6.3, range=2-9years, M/F=3/5). Inclusion criteria included a diagnosis confirmed by cultured fibroblasts cholesterol esterification rate analysis and filipin staining of unesterified cholesterol. In addition, patients must have been aged above 2-years and be neurologically capable of attending to the oculomotor assessment. There were no other exclusion criteria (e.g. none related to oculomotor control). Clinical scores were obtained for patients using
Yanjapnin NP-C Clinical Severity Scale [7] . Demographics and overall clinical scores are shown in Table 1 (detailed clinical scores in Appendix A). Three patients were neurologically asymptomatic and, in particular, did not have oculomotor abnormalities in clinical testing (pre-neurological NP-C, disability score=0). The two neurological patients (NP-C03 and NP-C05) had clinically observable mild/functional VSGP (i.e. vertically eye movements were not completely abolished, but initiation depended on the use of a proceeding head-thrusting and/or blinking). No patients were receiving medication for seizures (e.g. benzodiazepines)
that could disrupt eye movements. Patients were compared to data from 77 healthy controls with no history of major medical, neurological or psychiatric illness (mean age=11.86, range=2-20 years, M/F=43/34). were fit to control data and the best was selected using Akaike Information Criterion values (AIC) and Akaike weights [18] . AIC-based model selection is preferable to model selection using p-values because it emphasizes the weight of evidence for models in a candidate set.
_________________
One model or several models can receive support and there is an explicit trade-off between fit and number of model parameters to guard against overfitting [18][9] . This method distinguishes cases where several models provide relatively good accounts of the data (relatively equal probabilities split across several models) from cases where one model is clearly better than the others (one model has high probability, all others low).
We used linear mixed effects models (LME) for statistical analysis of developmental trajectories and group differences [19] . Random and fixed effects were selected using AIC following the method described by Diggle [20] . We report group analyses for pre-neurological patients, where we want to know if eye-tracking can reveal group differences that are not clinically apparent (and don't depend on the most severe patients). We expect to see differences between neurological patients and controls, and, in fact, these are usually apparent at the level of individual patients. We report individual results for all patients. In the group analysis, there were fixed effects for Group (to test for differences between patients and controls), Age (to test for differences in developmental trajectories) and Condition (to test whether abnormalities were confined to particular stimulus locations). Main effects of Group are found if performance is worse in the patient group across all ages. Interactions with Age occur if development is slower in the patient group, if it is slower at a particular stimulus location (Age X Group or Age X Condition interactions) or if the developmental trajectory is slower for patients in only some conditions (Age X Condition X Group interaction).
To examine performance in individual patients, we, first, calculated ninety-five percent prediction intervals for developmental trajectories in controls by fitting interceptonly, linear and quadratic functions to upper or lower 95% t-value cutoffs. We used AIC to choose the function that best described the trajectory of the upper or lower limit. Individual NP-C patients who were outside the prediction interval were reliably different from controls.
Individual patients were compared to controls using the equivalent of z-scores, calculated from the upper or lower endpoints of the prediction intervals, rather than from noisier agespecific samples. Our method smooths the prediction intervals, borrowing information from adjacent regions on the developmental curve, in the same way the function describing the mean is smoothed. We label these zpi. Results for individual patients did not highlight significant exceptions to this pattern.
Only the onset time of the youngest pre-neurological patient (2 years) was longer than Eye movement peak velocities depend on how far the eyes move. Velocities are systematically higher for longer saccades. This raises the question of whether developmental differences in peak velocity were driven by differences in saccade amplitude. To factor out the influence of amplitude, which will also be important when we turn to patient data, we predicted peak velocity using amplitude and then modelled the component of velocity left over after amplitude was factored out (velocity residuals).
There was still an interaction between age and condition (Condition X Age model Amplitude was also an issue when quantifying group differences in peak velocity.
Patients could have lower peak velocities either from slowing or simply because saccades often fell short of their targets. Plotting saccade amplitude and velocity together in Figure 2B shows that changes in velocity were not generally a simple consequence of making shorter saccades. Confidence intervals describing the control range of amplitudes and peak velocities (error bars) show that, for bottom targets, 3 patients were slower than controls, but only one had abnormally shortened saccades. For top targets, two patients were slow, but only one made shorter saccades. Our group analyses factor out these amplitude differences, by using velocity residuals, to quantify the component of velocity that is independent of the length of the saccade.
After factoring out amplitude differences, pre-neurological patients were slower than Table 2 summarises results from all measures in all directions. Horizontal movements are almost entirely unaffected by the disease. Vertical movements are often affected. Curvature is affected first, with changes apparent even in pre-neurological patients and peak velocity is also often affected. Saccade onset can be affected, but usually only when the disease is more advanced.
Discussion
We have presented a high resolution assessment of oculomotor function from a cohort of paediatric neurological and pre-neurological NP-C patients (i.e. with and without clinically apparent oculomotor impairments). In both groups of patients there were impairments in saccade velocity and saccade curvature. Vertical saccades were more affected than horizontal saccades as would be expected with greater cell loss in the brainstem nucleus RIMLF compared to the PPRF [12] .
Since excitatory burst neurons in the RIMLF are associated with peak saccade velocity and that RIMLF is known to be affected by the disease, velocity is a natural place to look for early signs of NP-C damage [12] . Velocity changes were, indeed, found in all of the neurological patients, as expected, and in one of the three pre-neurological patients. This is exactly the pattern that is desirable for a good indicator. Changes were apparent in eyetracking records before they were noticeable in the clinic, and they followed the pattern you would expect from a value that anticipates more serious changes to oculomotor control (i.e.
the changes were apparent in the older patients, where the disease is likely to be more advanced, but less strong in younger patients) The lag with which subtle changes to peak velocity anticipate more substantial changes and the consistency of this lag across individuals is an important topic for future research.
A new result was that saccade curvature was an equally early or even earlier index of changes. Curved eye-movements to oblique targets have been reported previously in NP-C [23] , but, given the way the eye-movement system is organised, curved saccades to oblique targets are expected when vertical movements are slowed. Oblique saccades become curved because the eye arrives at the horizontal target position earlier than the vertical position and the trajectory curves upward as the vertical component finishes late. In other words, curvature in oblique saccades is a simple consequence of velocity changes. Curved oblique saccades do not, however, predict that purely vertical saccades will also be curved. These should just be slower. We found that purely vertical saccades were curved, which cannot be explained by simple velocity changes.
Curved vertical saccades have been noticed before. Quinn [14] and Jitkritsadakul, Tansuhaj & Bhidayasiri [15] reported that early stage progressive supranuclear palsy (PSP) patients had curved saccades in the purely vertical direction. Leigh [16] speculated that this is an adaptive strategy whereby the patient starts to make a saccade with a horizontal component to increase the time available to generate the vertical component. Indeed, a recent case report describes an adult with NP-C who had severely affected downward saccades and upward saccades accompanied by a horizontal movement, which the authors interpreted as a strategic adjustment [24] . While an element of strategy cannot be ruled out in our patients, curvature was evident before vertical saccades were noticeably slower and the degree of curvature was relatively small, compared to what would be detectable without an eye-tracker, so a strategic approach seems unlikely. The neural organisation of RIMLF, however, offers a better explanation.
Curved saccades are predicted from the way the RIMLF nucleus is organised to code vertical movements. Neurons in the RIMLF do not code up-or downward movements in isolation. Instead each neuron codes both a direction (up/down) and a rotation around the axis that runs from the pupil down the line of sight (torsion) [11] . This is because vertical movements involve the oblique muscles, which are the main muscles responsible for torsional movements, in addition to the inferior and superior rectus muscles that move the eye directly up and down.
Crucially, Crawford and Vilis [11] , in their detailed study of RIMLF function, show that the neuronal populations dedicated to vertical movements do not code simple straight up and straight down directions. They code an oblique up or oblique down direction in addition to torsion (see their Figures 7 and 16 ). Normally, when RIMLF is coding straight vertical movements, the left and right oblique deflections cancel each other, in the same way that the torsional movements cancel, and movement is straight up or straight down. When one side of the RIMLF is inactivated, however, Crawford and Vilis noted that eye-movements had a left or right deflection in addition to slowing in the vertical direction. This means the coding system predicts exactly what we found in patients. When populations of neurons that must normally counterbalance are affected by disease, the eyes will be driven obliquely toward the side pointed to by the stronger population.
This explains the initial deflection, but not the return to the target. For the eyes to curve back toward the target position, eye-movements must be under the feedback control of an unaffected centre above the level of the RIMLF. In other words, there must be a level where the target is coded in the correct position that will force a correction. This also fits, however, current standard assumptions about eye-movement control [10, 25] . The exact details of how and where feedback control is implemented are still under investigation, but there is agreement that a copy of the signal from RIMLF (a corollary discharge, which will contain the oblique error) is compared to the intended eye-position (under control of the superior colliculus) and the eye position is modulated until the error is eliminated [10, 25] .
Two additional predictions follow from these accounts. The first is that curvature will be systematically to one side for up or down saccades and the second is that curvature will begin at the start of the saccade. Neither of these would follow from a source of measurement noise or an artefact that affects vertical measurements. It is clear from Figure 3 that both of these predictions were substantially upheld (only NP-C 03's upward saccades showed curvature on both sides of the vertical, and this is one of the most severe patients). In fact, movements up and down are not only consistently to one side, they tend to be curved to opposite sides for up and down movements. This is what Crawford and Vilis found when they inactivated one side of the RIMLF at a time. Horizontal deflections were to opposite sides for up and down saccades.
We assume, in the absence of other information, that NP-C will randomly affect populations of neurons in the RIMLF. Random damage is not guaranteed to affect one side of the nucleus more strongly, but that will often be the case. Following the logic of random damage affecting a bilaterally arranged structure, it should be possible for damage to be relatively equally spread across right and left RIMLF. This means that slowed saccades without curvature are possible, but should occur relatively rarely. In addition, as damage progresses, curvature could become either more or less pronounced. It is not guaranteed that the asymmetry will always get worse with time. As damage becomes more complete, in fact, there may be a tendency for slow or hypometric saccades to dominate, with curvature a less prominent feature.
As damage to RIMLF progresses, the total number of burst neurons firing in any part of the RIMLF will get noticeably smaller. Velocity and, eventually, saccade onset itself should be affected. This was the pattern we observed (see Table 2 ). The early appearance of curved saccades and velocity changes raises the possibility that video-based oculomotor measurement could improve the sensitivity with which disease progression is tracked in NP- although the exact scale and time course and the variability of changes will need to be followed in a larger sample. Longitudinal follow-ups could help us to understand the natural time course and degree of individual variability in the disease. Longitudinal data may also allow us to detect neurological involvement even earlier than we have been able to do here. This is because an individual's trajectory of change could be noticeably abnormal before the absolute level of performance, at any single point, has exited the control range.
Conclusion.
High-resolution video-based eye-tracking, using simple fixation tasks, can identify oculomotor changes in NP-C children earlier than is possible with clinical oculomotor assessments. A promising new metric, saccade curvature, measured impairments in patients both with and without diagnosed neurological involvement and peak velocity was also low in some pre-neurological patients. Longitudinal studies should be used to confirm our measures as a good marker of neurological onset and explore using them to monitor treatment effects in children with NP-C. Eye-tracking is high precision, but the tasks are relatively simple, quick and easy for children to do. Comparison with robust control data can highlight individuals who fall outside the normal range, and the approach we have outlined here is ideal for both clinical decision-making and working with data from rare diseases.
Future studies could investigate the utility of eye tracking data to screen for NP-C in populations of patients that present with symptoms that are associated NP-C, for example, in patients with early-onset ataxia and / or frontotemporal dementia. It is thought that NP-C may be undiagnosed in some patient groups that display symptoms associated with NP-C, but where the symptoms are not diagnostic on their own [26] [27] [28] . Eye-tracking measures could contribute to identify those patients that warrant further follow-up investigation. Table 1 . NP-C patient demographics and neurological scores. 
